Quinn Opportunity Partners’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-41,418
| Closed | -$188K | – | 372 |
|
|
2025
Q3 | $188K | Hold |
41,418
| – | – | 0.01% | 283 |
|
|
2025
Q2 | $89K | Hold |
41,418
| – | – | 0.01% | 328 |
|
|
2025
Q1 | $181K | Buy |
41,418
+14,589
| +54% | +$65.8K | 0.01% | 345 |
|
|
2024
Q4 | $125K | Hold |
26,829
| – | – | 0.01% | 350 |
|
|
2024
Q3 | $188K | Hold |
26,829
| – | – | 0.02% | 245 |
|
|
2024
Q2 | $184K | Hold |
26,829
| – | – | 0.02% | 234 |
|
|
2024
Q1 | $379K | Sell |
26,829
-13,001
| -33% | -$198K | 0.04% | 188 |
|
|
2023
Q4 | $300K | Hold |
39,830
| – | – | 0.03% | 183 |
|
|
2023
Q3 | $597K | Hold |
39,830
| – | – | 0.08% | 150 |
|
|
2023
Q2 | $633K | Hold |
39,830
| – | – | 0.09% | 131 |
|
|
2023
Q1 | $286K | Hold |
39,830
| – | – | 0.03% | 194 |
|
|
2022
Q4 | $231K | Sell |
39,830
-2,000
| -5% | -$15.2K | 0.03% | 161 |
|
|
2022
Q3 | $397K | Sell |
41,830
-8,470
| -17% | -$111K | 0.05% | 140 |
|
|
2022
Q2 | $604K | Hold |
50,300
| – | – | 0.05% | 142 |
|
|
2022
Q1 | $659K | Hold |
50,300
| – | – | 0.03% | 129 |
|
|
2021
Q4 | $885K | Buy |
50,300
+25,500
| +103% | +$510K | 0.05% | 145 |
|
|
2021
Q3 | $538K | Hold |
24,800
| – | – | 0.03% | 194 |
|
|
2021
Q2 | $868K | Buy |
+24,800
| New | +$1.34M | 0.05% | 165 |
|
Quinn Opportunity Partners's ADVM Position: Q4 2025 in Review
Quinn Opportunity Partners sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 41,418 shares — an estimated $188K sold.
Quinn Opportunity Partners first reported a position in ADVM in Q2 2021 and held it in 18 quarters. The position peaked at $885K in Q4 2021. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Quinn Opportunity Partners reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Quinn Opportunity Partners sold 41,418 Adverum Biotechnologies shares in Q4 2025, an estimated $188K.
- Quinn Opportunity Partners first reported a position in Adverum Biotechnologies in Q2 2021 and held it in 18 quarters.
- Quinn Opportunity Partners's Adverum Biotechnologies position peaked at $885K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Quinn Opportunity Partners's 13F filing for Q4 2025, filed 13 Feb 2026.